Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 331 trials

Meniscal Pain Relief: Betamethasone Infiltration Study

We are testing whether ultrasound-guided betamethasone injections can reduce pain in adults with degenerative meniscal injuries. This study compares the treatment to a placebo to assess its effectiveness and safety.

Meniscal Pain3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Tocilizumab for Painful Chronic Pancreatitis

We are studying whether tocilizumab can help reduce pain and improve quality of life for people with chronic pancreatitis. The trial will compare its effects to a placebo treatment.

Chronic Pancreatitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Overactive Bladder in Children: BeDry Study

We are testing solifenacin, mirabegron, and their combination for treating daytime urinary incontinence in children aged 5 to 14. The study aims to see how well these treatments work and their effects on safety and quality of life.

Daytime Urinary Incontinence3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesPediatricsUrology

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyNeurology

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Acne Vulgaris: N-Acetyl-GED-0507-34-Levo Gel

We are testing a new gel for people with acne vulgaris to see if it is safe and effective compared to a placebo. Participants will apply the gel once daily for the study.

Acne3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Pancreatic Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons better see pancreatic tumors during surgery. This study aims to improve the accuracy of tumor detection and assess the extent of cancer in patients who have received prior treatment.

Pancreatic Tumor3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Personalized FOLFIRINOX Dosing Study

We are exploring how personalized dosing of the chemotherapy drug 5-FU affects safety and treatment outcomes in pancreatic cancer patients. This study aims to find the best dosing strategy to improve effectiveness and minimize side effects.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Chronic Migraine: Eptinezumab for Teens

We are studying whether eptinezumab can help reduce the number of migraine days in adolescents aged 12 to 17 with chronic migraine. This trial compares the medication to a placebo to assess its effectiveness.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Soft Tissue Sarcomas: Atezolizumab with Radiotherapy

We are studying whether adding an immunotherapy drug to radiotherapy helps patients with localized soft tissue sarcomas achieve better treatment outcomes. The trial will also look at the safety and immune response to this combination.

Localized Soft Tissue Sarcoma3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Hyperbaric Oxygen Therapy for Sudden Hearing Loss

We are studying whether adding hyperbaric oxygen treatment to standard care improves hearing in people with sudden sensorineural hearing loss. The trial will also look at quality of life and safety of this treatment approach.

Sudden Hearing Loss3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOtolaryngology

Post-Stroke Spasticity: Dry Needling vs. Botulinum Toxin

We are exploring how Dry Needling and Botulinum Toxin type A affect spasticity in the lower limbs of stroke survivors. The study will also look at safety, muscle function, and quality of life.

Spasticity after Stroke3-6 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Prolonged Seizures: Staccato Alprazolam Study

We are investigating whether Staccato Alprazolam is safe and effective for quickly stopping prolonged seizures in individuals aged 12 and older. The study compares its effects to a placebo to assess its benefits.

Prolonged Seizure3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Advanced High-Grade Osteosarcoma: OMO-103 Treatment Study

We are testing a new drug, OMO-103, to see if it can help treat advanced high-grade osteosarcoma in patients aged 12-15. The study will assess its safety and how it impacts the patients' quality of life.

Metastatic Osteosarcoma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ampullary Adenocarcinoma: mFOLFIRINOX vs. Gemcitabine or Capecitabine

We are studying whether a combination chemotherapy can improve survival rates for patients after surgery for ampullary adenocarcinoma. The trial also looks at quality of life and side effects compared to standard treatments.

Ampullary Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Capsaicin for Finger Pain in Osteoarthritis

We are studying whether a stronger capsaicin cream can reduce finger pain better than a lower dose in people with digital osteoarthritis. This trial also examines its effects on daily function and overall quality of life.

Finger Osteoarthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology